Home / Transcripts / Nufarm Limited (NUF) · November 18, 2026

Nufarm Limited (NUF) Earnings Call Transcript

November 18, 2026

Australian Securities Exchange AU Materials Chemicals earnings 63 min

Earnings Call Speaker Segments

Rico Christensen executive
#1

Thank you, Abby. Good morning, and thanks for being with us for Nufarm's FY 2026 full-year results; joining me today are Brendan Ryan, our CFO, Beth Lorsbach, our Group Executive for Portfolio Solutions, and Rachel Palumbo, who is General Manager of our Seeds business. These are strong results. Earnings have risen, the quality of those earnings is stronger, cash flow has improved markedly, and leverage now sits at 2.0 times. Our refreshed strategy has hit every key metric and put us on a positive course toward even better returns. I'll begin with the group result, then walk you through crop protection and Seed Technologies in more depth. After that Brendan will cover the financials, and I'll finish with our outlook for FY 2027. Before we start, I'd encourage everyone to read the important notices on page two about forward-looking statements and non-IFRS measures. As ever, what we say today is subject to market conditions and the risks set out in this presentation. We're pleased with how we performed this year, both on improved financial performance and on the progress of the strategy refresh. Earnings have risen, and importantly, the quality of those earnings is stronger, cash flow has improved markedly, and leverage is lower. Our refreshed strategy has hit every key metric and put us on a positive course toward improved returns. Underlying EBITDA rose 25% to AUD 378 million, on revenue that came in 7% lower. We've prioritized margin over volume, and it's paying off. Our underlying EBITDA margin widened by 3.0 percentage points to 11.8%, while underlying gross margin is up 3.2 percentage points to 30.8%. In fact, underlying EBITDA margins improved in every business segment across crop protection and Seed Technologies. The revenue decline reflects very strong growth in Seed Technologies, offset by our deliberate choice to pull back from lower-margin sales in crop protection, along with some currency translation headwind. Underlying NPAT came in at AUD 20 million, against a loss of AUD 23 million a year earlier. That profitability is now visible in cash. Free cash flow was positive AUD 28 million, a AUD 158 million improvement year on year, and leverage has fallen from 2.7 to 2.0 times. Return on funds employed increased 3.1 percentage points to 5.9%. That's a good step forward, though it comes off a low base, and we know there's still some way to go. The statutory result includes AUD 99 million of after-tax material items, mainly non-cash, tied to the actions we're taking under the strategy refresh. Back in November, we laid out three unambiguous goals for the year: discipline on cost and capital, profitable growth within crop protection, and execution of our reprioritized seed strategy; on each of those three, we have delivered exactly what we promised; regarding cost and capital discipline, underlying EBITDA rose 25%, free cash flow came in positive, and we cut leverage by 27%; we additionally captured AUD 57 million in savings through our 2025 program, and the 2026 program targeting AUD 50 million in savings remains on track; for crop protection, the goal was profitable growth together with better earnings quality. Our underlying EBITDA margin widened 1.3 percentage points, helped by improved mix and disciplined costs. Reported underlying EBITDA fell 1%, weighed down by currency translation and one-off items, among them the manufacturing disruptions at Laverton and Wyke. Leaving those aside, underlying EBITDA was up 3.7%. Gross profit in crop protection likewise improved, and that is where the refreshed strategy is becoming visible; in Seeds, FY 2026 was a record year on both revenue and profitability. Underlying EBITDA for Seeds climbed 22%, and Renewable Oils turned in positive underlying EBITDA. Sadly, I must pass along some tragic news; a road accident in Brazil took the life of one of our teammates. That should never happen. He had undergone safe driving training and had a driver safety system installed in his vehicle. Even so, it plainly did not perform the way we intended. Since that accident, we have thought carefully about how we can improve. One important step involves broadening deployment of driver safety systems across our fleet vehicles worldwide and also enhancing how we use those systems to encourage safer driving; we ran a global safety, health, and wellbeing survey across our employees and are working through what it taught us. We are additionally launching a globally consistent framework for health and safety objectives for FY 2027, aimed at strengthening accountability among our people leaders and fostering a stronger safety culture. We have to do better. With that somber note, allow me to give you somewhat more detail on our crop protection business. Within crop protection, the refreshed strategy is reshaping what our earnings are made of. This bridge illustrates how. Begin with underlying growth: once currency and one-off factors are excluded, underlying EBITDA increased. Several one-off items, among them currency translation, the manufacturing disruptions at Laverton and Wyke, and U.S. tariffs, pulled that back to a 1% decline in reported underlying EBITDA. Margin and mix are the crucial point. We are intentionally scaling back lower margin business while directing more effort toward higher margin products. Revenue has come down as a result. Yet the favorable margin and mix effect outweighs that revenue decline by more than enough, which explains the margin expansion. Gross profit in crop protection has risen, and underlying EBITDA margins have improved across every region. What this means is that the makeup of our earnings is shifting. We're making more money on every dollar of sales, and we're achieving that while using less working capital and less capital employed. That's what we mean when we talk about improved earnings quality, cash flow, and returns, and it's exactly what the strategy refresh is built to deliver. Now I'll walk you through how this is unfolding region by region. Crop protection saw better earnings quality and margin expansion, driven by mix and cost discipline. The regions follow that same pattern, though each starts from a different point. In Asia Pacific, the underlying EBITDA margin rose by 1.1 percentage points. Asia grew, with Indonesia as the key contributor. Reported underlying EBITDA was held back by the manufacturing incident at Laverton and by currency translation. If you exclude those two items, underlying EBITDA grew year-on-year. Revenue in the region came in 10% lower, so a flat result on lower revenue with a higher margin is a good outcome. In Europe, the margin went up by 0.7 percentage points, including the continuing benefits of the performance improvement program. The fourth quarter manufacturing disruption at Wyke and currency translation held back reported underlying EBITDA, which was down 1%. North America is the main focus of the strategy refresh, and it's where we have more work to do. We're reducing our exposure to lower value commodity business, and that, along with softer market conditions, brought revenue down. Underlying EBITDA was down 3%, which is partly currency translation, and note that the benefits of the footprint and product rationalization haven't yet shown up in cost. Beneath the surface, the mix is improving, with good performance in Turf & Ornamental, Canada, and Mexico. I'll return to what we're doing in North America on the next slide.

Rico Christensen executive
#2

In September, at our strategy update, we conveyed the following: one strategy, with regional priorities matched to our strengths and to where opportunities exist. Today I want to demonstrate the tangible progress achieved on those priorities in every region. Regarding Asia Pacific, the aim is to strengthen our position and expand where we are best positioned. Asia recorded its highest underlying EBITDA ever in local currency. In Australia, margins rose because of an improved portfolio mix, demonstrating that the strategy refresh is delivering results. We are also proceeding toward the closure of our Kwinana plant, ensuring our footprint matches a tighter portfolio. Further out, we are moving Attero, our new herbicide, toward a 2028 launch. For Europe, what we're concentrating on is taking performance further. Excluding the Wyke disruption in Q4, European earnings were up compared with a year earlier. Operational control of Wyke now sits with PX Group, which brings scale along with specialist operating know-how to that site. Turning to North America, returns are the priority; we're expanding in Turf & Ornamental and in Canada, while removing approximately 280 SKUs — about 25% of the range. What that gives us is a tighter portfolio with reduced complexity. The bulk of the revenue drop in North America stemmed from our choice to exit certain low-margin commodity business. We're also moving forward with shutting down our Alsip facility. Those steps are what I referenced on the prior slide, and we expect the cost-reduction benefits in full during FY 2028. The specific moves differ from region to region, yet the goal remains unchanged: improved margins and stronger returns on the capital we deploy. For FY 2026, our innovation rate came in at 13%, consistent with historical levels; this represents the portion of sales derived from products that are new to a given country over the past five years. It demonstrates that the portfolio is being refreshed even while we concentrate it more narrowly. The slide includes a number of product examples. Partnerships will continue to drive our portfolio renewal, delivering innovation through a capital-light model. I want to use this moment to express appreciation to our technology partners for backing us and for continuing to see Nufarm as a solid partner for taking products to market. Moving on to Seed Technologies now. In Seed Technologies, we achieved record results on both the top line and profitability. Revenue was up 34%, reaching AUD 449 million, while underlying EBITDA came in at AUD 86.4 million, an increase of AUD 72.5 million. Seeds is the platform into which we are putting investment, and these numbers demonstrate the reason. Revenue rose 16% to AUD 293 million, and underlying EBITDA climbed 22% to AUD 82 million. The underlying EBITDA margin improved by 1.3 percentage points, reaching 28%. Canola posted growth in Australia as well as South America, and launches of new products contributed to the outcome. Renewable Oils has reached profitability at the underlying EBITDA level, and that's a AUD 58 million gain versus a year ago. Here's what's driving it. Omega-3 oil sales are the biggest factor, supported by better pricing, plus the absence of last year's inventory impairment, which didn't recur. Two things give this more durability: our work to cut the cash needed in omega-3, and the bp Carinata agreement extension, which I'll cover shortly. Overall, Seed Technologies is delivering just what we set out to do: growth alongside better margins and stronger capital discipline when choosing which technologies to support. Seeds remains an investment priority because of its high margins and strong growth track record. Across the past five years, Seeds revenue has expanded by an average of 13% each year, and in FY 2026 it posted record revenue along with an underlying EBITDA margin of 28%. This is the platform within Seed Technologies that we have chosen to put investment behind. The market is underpinning that growth. Demand for edible oils and biofuels, combined with the economic advantages of these crops, is fuelling structural demand growth. During the last three years, canola area planted in Argentina, Uruguay, and Brazil has increased 14% annually, while sorghum in Argentina and Brazil has risen 10% annually. Brazil saw a record year for both crops. Our own results tell the other half of the story. For canola revenue, fiscal 2026 set a record, driven by expansion in both Australia and South America. Our acquisition of Mojo—a sorghum specialist—also deepened our differentiated standing in North America. Renewable Oils is the segment where our investment approach has been most deliberate. The opportunity there is real, and we tie capital deployment to the commercial milestones we reach. Take Carinata first. During the year, we extended the offtake arrangement with bp all the way to 2050. That extension supports Carinata's growth as a non-food biofuel feedstock. In omega-3, we have lowered cash cost and trimmed the capital we allocate, and we are aligning investment with the commercial milestones achieved. Final food and feed use clearances are in hand for Japan, while regulated field trials continue in Argentina. The demand picture looks supportive. In Europe, RED III rollout is strengthening demand for biofuels, and Germany’s greenhouse gas quota is set at EUR 400 per ton of CO2 equivalent. Supply of fish oil remains tight as well, with North Atlantic fish oil trading around $7,000 per ton, near record levels. That supports omega-3 oil pricing. We take a disciplined approach; we keep the long-term upside in view while capping cash outlay before milestones are achieved. I’ll now hand over to Brendan, who will go through financial performance in more detail.

Brendan Ryan executive
#3

Appreciate that, Rico. Rico already walked through it, but a crucial piece of this outcome is the way profit sources have been reshuffled, and you can see it clearly in the P&L. Top line declined 7% since we pulled back on business carrying thinner margins, particularly crop protection. Gross profit rose, with the margin rate expanding 3.2 percentage points to 30.8%, supported by an improved crop protection blend, expansion in Seeds, and a bigger lift from omega-3. Net operating expenses also fell, reflecting gains from the 2025 cost program, through which we achieved AUD 57 million in savings. All of that combined drove underlying EBITDA 25% higher to AUD 378 million and doubled underlying EBIT to AUD 165 million. Our EBITDA margin improved by three percentage points, reaching 11.8%. We also saw financing costs come down by 10%, although FX hedging costs partially cancelled out that gain. Underlying net profit after tax swung from a loss of AUD 23 million to a profit of AUD 20 million. On a statutory basis, we recorded a loss of AUD 80 million, following AUD 99 million in after-tax material items. Those items were mostly non-cash and were largely connected to the steps we're taking as part of the strategy refresh. Despite lower revenue, we're generating more profit from that revenue. A better mix, a higher gross margin, and a reduced operating cost base are collectively driving stronger operating leverage through the P&L. Let me now turn to the balance sheet. We're now seeing stronger cash generation and improved capital efficiency, and those have reinforced the earnings gains. Average working capital has declined to the low end of our target range. After a stretch of heavier investment, capital expenditure has been reset, and net debt decreased 9% to AUD 749 million. Combined with EBITDA growth, that took leverage from 2.7 times down to two times — delivering the target we set a year ago. Return on funds employed climbed from 2.8% to 5.9%. As Rico noted, that's still short of where we'd like it, but the trajectory is clear, and it reflects both better profitability and disciplined capital deployment. Overall, our balance sheet has strengthened. Better earnings, stronger cash generation, and greater capital efficiency have all contributed to reducing leverage. Now I'll take you through the main factors driving that improvement. Regarding costs, the 2025 program has finished. We achieved AUD 57 million in savings versus the initial AUD 50 million goal, and those benefits are reflected in this year's results—part of the reason net operating expenses came in 5% below the previous year. The separate program announced in April is aimed at an additional AUD 50 million. We anticipate reaching that run rate by the close of FY 2027, with the full benefit arriving in FY 2028. Roughly sixty percent of the targeted savings is expected to come from our manufacturing cost base, while about forty percent would come from SG&A. Those savings are linked to actions that are already in motion: the closures at Kwinana and Holstebro, the SKU rationalization in North America, and the restructuring of the European Seeds portfolio. As Rico said, the benefits from the cost savings associated with the footprint and portfolio changes have yet to flow through, and they are weighted toward the second half of FY 2027. Moving to cash flow, this represents a significant shift from FY 2025. Free cash flow rose by AUD 158 million, hitting a positive AUD 28 million, with free cash flow before tax and financing costs of AUD 207 million. That gain was driven primarily by stronger profitability along with a smaller and more disciplined capital envelope. A year ago, we indicated that the steps we were taking ought to result in positive free cash flow in FY 2026, and that is exactly what has occurred. From this point, additional room exists to enhance cash conversion. FY 2026 marks a clear move forward. Crucially, that stronger cash generation is feeding through into reduced net debt and leverage. Working capital provides yet another key proof point. Average net working capital sales fell by another 2.1 percentage points, reaching 36.1%, which sits toward the lower end of our 35%-40% range, while the cash conversion cycle improved by five days. Another key point is that average net working capital now sits at roughly AUD 400 million under the peak we saw in the first half of 2024. That gain has held for two years. Net working capital finished the year 12% lower. Some of this stems directly from the portfolio decisions we've made. With less low-margin commodity business, we carry less inventory and have fewer receivables to finance. That margin call is also lifting capital efficiency. Turning to capital expenditure: capital expenditure, or D&A, is shown on an accrual basis, so it captures amounts incurred even where cash payment hasn't happened yet. We intend to keep capital expenditure under AUD 200 million. That shows tighter discipline in how we allocate capital, in line with a sharper strategy. That decrease comes from spending less on manufacturing, putting less money into omega-3, and ranking priorities more sharply throughout the portfolio. The key point is that we aren't pulling back from investing. We're simply picking our spots more carefully. The money is going toward maintaining the asset base we already have and toward the Seeds and Crop Protection opportunities that offer the best returns; that tighter approach to capital helps free cash flow and our capacity to put money into growth and lift return on funds employed as time goes on. Last, net debt. It fell by AUD 76 million, and leverage went from 2.7 times down to two times — a 27% drop, in line with the goal we set at the start of the FY 2026. What really matters is that this gain came from stronger earnings, working capital that's working harder, and less spent on capital projects. With net debt lower, we should see financing costs come down as time goes on, which opens another route to better earnings and cash flow. Our debt maturity profile has been lengthened — the standby liquidity facility now runs to November 2028 — and the refinancing of the AUD 800 million ABL facility is moving ahead. We closed FY 2026 with stronger earnings, free cash flow in positive territory, less net debt, and leverage down substantially. The key point is that these results match up with what we promised a year ago. As we head into FY 2027, we have a solid financial foundation and more chances to strengthen cash generation and returns. At this point I'll turn things back to Rico Christensen, who will walk through the FY 2027 outlook.

Rico Christensen executive
#4

Appreciate that, Brendan. That sets up nicely for what we anticipate in FY 2027. FY 2027 has begun well for Nufarm, with trading tracking to plan. As our refreshed strategy continues to be implemented, we expect FY 2027 to deliver additional improvement in earnings quality, cash flow, and return on funds employed. Barring unusual seasonal patterns or currency translation surprises, we expect underlying EBITDA to continue rising — mid-teens underlying EBITDA growth in Seed Technologies and mid-single-digit underlying EBITDA growth in crop protection, with corporate costs unchanged versus the prior year. The payoff from our strategy refresh is likely to land more heavily in the back half of FY 2027, and we'd see the complete effect by FY 2028. Capex is projected to remain under AUD 200 million. We're looking at D&A expense of roughly AUD 215 million, underlying net financing costs — FX hedging included — of about AUD 100 million, and an underlying tax rate in the 40%-45% range. Free cash flow ought to strengthen, net debt is expected to come in lower than FY 2026, and by the close of the year leverage should be inside our long-term target band of 1.5 to 2 times. Our cost reduction initiative for 2026 is proceeding as planned. We anticipate achieving AUD 50 million in annualized savings by the close of FY 2027, with the majority of those savings landing in the latter half and the complete advantage realized in FY 2028. Naturally, this guidance is forward-looking and carries the risks described in the disclaimer. Ahead of opening the floor to questions, I'd like to summarize the four main takeaways from today. First, the result is a robust one. Underlying EBITDA rose 25%, and our underlying EBITDA margin widened by 3%; we prioritize margin above volume. The profits we report now are of superior quality. Second, that quality is being turned into cash. We generated positive free cash flow of AUD 28 million — that's a AUD 158 million swing versus last year — and leverage has come down to two times from 2.7 times. Third, the payoff from our strategy refresh shows up in better margins across crop protection and Seeds, as well as in the expansion of our Seeds platform. Underlying EBITDA margin for crop protection rose 1.3 percentage points, while Seeds posted record revenue and underlying EBITDA. Fourth, there's still work ahead. Return on funds employed improved to 5.9%, but that's still off a low base; come FY 2027, we anticipate further gains in quality of earnings, cash flow, and returns. To finish up, I'd like to express appreciation to our customers for sticking with us, and likewise to our worldwide teams for delivering this outcome. This result came from your efforts. Thanks very much. On that note, Brendan, Rachel Palumbo, Beth Lorsbach, and I are ready to take your questions. Over to you, Abby.

William Park analyst
#5

Morning, Rico, Brendan, and everyone on the team. Thank you for taking my question. First off, could I ask about what I suppose is the effective tax rate jumping sharply during the second half of FY 2026? Brendan, I believe you mentioned that a non-cash tax element is behind this. Could you walk us through what caused it? Clearly, you're guiding toward a 40%-45% tax rate across the full year in FY 2027. How ought we to think about tax rates in the first half of 2027 compared with the second half of 2027? And could you confirm whether it then goes back to roughly the 30% level after FY 2027?

Rico Christensen executive
#6

Yes. Thanks, William. Yes, there are a few points to walk through regarding the underlying tax rate. First, seen from a cash tax standpoint, it stays fairly steady, although we keep optimizing cash tax across the group as a whole. That aligns with corporate tax rates of roughly 25%-30%, varying by jurisdiction. The variability arises in the non-cash side, which concerns deferred tax. Nufarm sits within several tax groups, so, for instance, the U.S. tax group and the U.K. tax group, and those tax groups carry differing profit and loss profiles. As earnings keep improving across the group, the underlying effective tax rate will keep coming down, as we have indicated, from 2026 into 2027, and after that we would expect it to normalize over time to roughly 30%; regarding some of the specifics for this year and the changes in the business, one element is, for instance, the omega-3 effect of shifting the production zone from North America down to South America. What that does is move profit from one jurisdiction to another; so overall there is no net economic loss across the group, but the tax group in which it shows up changes. Then the overall effect of that is that we take what I would call a prudent approach to how we recognize deferred tax assets. We have done that in relation to material items as well. So we are focusing on using the deferred tax assets already on the balance sheet and not adding to them until we see the underlying profit progression coming through from the group and then flowing through into the underlying tax groups.

William Park analyst
#7

Thank you. That's very clear. So just on the growth question, specifically regarding crop protection and Seed Technologies. I appreciate that you're seeing a strong start to FY 2027, but may I just ask about the mid-single digit improvement that you expect from crop protection? Is that a result of you continuing to streamline the portfolio? So essentially a case of lower volume being more than offset by margin and mix once again? That's for crop protection. For Seed Technologies, I just wanted to understand how you're thinking about the growth profiles across hybrid seeds and, I suppose, Renewable Oils or the Emerging Platforms business?

Rico Christensen executive
#8

Thanks, brother. On crop protection, I think you almost answered your own question. Yes, that's exactly what we're seeing; we're still in the second year of the strategy refresh, so we're prioritizing margin over volume. We won't get the full effects until FY 2028, as we mentioned earlier. So we'll see some improvement in 2027, and as we said, it will be weighted towards the second half, but the full impact won't come until 2028. There's probably also a little bit of softer market conditions mixed in that we saw in the second half in North America in FY 2026. So we're going into FY 2027 basically with what we're seeing in the market today; we're not assuming improved pricing conditions or anything else. We're going with what we know in the current, and that's what's defining the outlook for FY 2027. On seeds, maybe Rachel Palumbo can provide a little more detail on the growth plans for seeds in FY 2027.

Rachel Palumbo executive
#9

Yes, thank you, Rico. When we look ahead to FY 2027, our main emphasis is on carrying on with the same discipline that helped us deliver our FY 2026 results, and we see appealing chances to grow throughout the portfolio. The structural demand we observe in food, feed, and fuel is really what supports that. South America continues to be an especially compelling opportunity for us, given that planted hectares are expanding across our key crops, and in Australia we keep seeing opportunities through our canola product pipeline.

William Park analyst
#10

Thanks. One final question, and it relates to your underlying EBITDA guidance. If I assume 15% growth in Seeds and 5% for crop protection, with corporate costs roughly flat, that gets you more or less to the consensus expectation for FY 2027. Regarding the cost savings you've identified from that 2026 program, how much of it is reflected in the FY 2027 guidance, and which key upside or potential downside factors would you say are worth flagging as we sit here today?

Brendan Ryan executive
#11

Yes, so within 2027 only a portion of the benefit from the 2026 program's cost savings is included, and that portion is weighted toward the second half of 2027. As a result, most of the savings will come through in financial year 2028. On where we stand with that, the goal is to reach the run rate by the close of this financial year. The activities are already underway, and things are progressing well, with confidence in delivering that number.

William Park analyst
#12

Thanks so much.

Ramoun Lazar analyst
#13

Yeah. Morning, everyone. I’ve got a few questions. Perhaps a little more detail on the crop protection side. Just the Wyke effects and the rebound there, I suppose that is included in the FY 2027 guidance, which could suggest that your underlying assumptions about the end markets are roughly flat to somewhat lower. Is that how we should view the underlying conditions once you remove the fact that plant outages will not recur in 2026?

Rico Christensen executive
#14

Perhaps I can take that one. I believe I also said earlier that the EBITDA growth we see in crop protection for FY 2027 really comes from the actions we are taking. We are not relying on better market conditions for those numbers, if that answers your question. So regarding manufacturing disruptions, we are planning for what is obviously a normal manufacturing year. We will have some catching up to do on manufacturing volumes from our sites, and that is also why we see part of the benefits more in the second half than in the first half.

Ramoun Lazar analyst
#15

Got it. Rico, perhaps regarding the Seed business and the growth platforms, could you share how you're approaching the planning for omega-3 heading into 2027, especially considering the quite favorable pricing environment? If possible, could you describe what you're observing broadly when it comes to that pricing environment and whether high prices can be sustained?

Rico Christensen executive
#16

Yes, that's a good question. As we exit FY 2026, we hold some inventory that we'll be commercializing during FY 2027. We aren't doing commercial planting. We didn't undertake commercial planting a year ago, and we also have no plans for commercial planting in FY 2027. There are certain regulatory trials we're progressing with in Argentina, but that's the full scope of our omega-3 activity. We remain highly focused on maintaining discipline in how we allocate capital and manage risk within that business.

Ramoun Lazar analyst
#17

All right, that's useful. Perhaps one final question, about omega-3 only. Is there anything new regarding the deregulation process in China?

Rico Christensen executive
#18

At present, we continue to assume approval in 2028.

Ramoun Lazar analyst
#19

Alright, that's all from me. Thank you.

Ollie Ridge analyst
#20

Morning. I wanted to ask about North America; revenue declined in the second half and EBITDA was down in constant currency. Could you give us a bit more detail on what's driving that weakness? Is it inventory being drawn down in the supply chain, are farmers using lower volumes, or are farmers trading down, please?

Rico Christensen executive
#21

We did experience some softness in North America during the second half. As I mentioned earlier, our FY 2027 expectations are being built on what we're seeing in the market right now, including how things stand in North America. There are probably several factors behind it. We saw a bit of volatility in commodity pricing, particularly corn, which rose somewhat in the second half but has since fallen back again. North America has been somewhat of a mixed bag, so to speak. On the whole, we believe market volumes are lower, and that's also what we're seeing from our peers; in our case, the actions we took, essentially cutting back lower margin business, which tends to be volume-related, also weighed on our North American business in FY 2026. Many of the benefits from those actions only arrive during FY 2027, as I said earlier, with the full impact coming in FY 2028.

Ollie Ridge analyst
#22

Thanks a lot for that. Right now, with the dry conditions over in Europe, operations are tough in North America. What makes you confident about the weighting toward the second half that's implied or stated in your guidance?

Rico Christensen executive
#23

I think a question came up. Was that a question about Europe? I didn't quite catch it.

Ollie Ridge analyst
#24

I was basically pointing out that Europe has dry conditions right now. North America is difficult too. I just wanted to ask why your FY 2027 guidance implies that weighting toward the second half?

Rico Christensen executive
#25

Got it. Yes. Like I mentioned before, the FY 2027 expectations really center on the steps we are taking. As I mentioned before, we are not counting on better market conditions. We plan for a normal season, which is what we always do as we enter a new year, but we are not planning for any improvement in market conditions. So when we describe it as weighted toward the second half, that reflects the actions we are taking around the strategy refresh and removing cost from the business.

Ollie Ridge analyst
#26

Thanks so much for all of that.

John Purtell analyst
#27

Good morning, Rico and Brendan. I hope the two of you are doing well. First off, a question about working capital and cash flow. I mean, usually we kind of see working capital released in the second half, and that has happened, and then it builds back up in the first half. Do you expect a normal seasonal build in working capital during the first half, or do you think you can smooth that out somewhat?

Brendan Ryan executive
#28

Yeah, thanks for the question, John. Look, it will be fairly typical compared with what we have seen in prior years, although what we are focused on is achieving a lower average across the course of the year, as well as at the specific points, particularly year-end when it comes to cash flow. So the rationalization of the portfolio and the choices we are making around the SKUs will give us some working capital benefit as we move through the course of the year. But in the grand scheme of things, the build in the first half and then the release in the second half will be typical of prior years.

John Purtell analyst
#29

Thank you. Just to go back to that question about the first half versus second half phasing, just to be clear, I mean, normally we do see a stronger first half EBITDA on a seasonal basis. This year, as just reported, I think it was, what, 64%. The few years before that were closer to 70. Should we think about a skew broadly in line with the 2026 level? Any comment on that would be helpful, please.

Brendan Ryan executive
#30

Yeah, John, it's somewhat more weighted in terms of what we expect for the second half. So a heavier weighting toward the second half than has been typical if you look at 2026. As Rico sort of outlined, look, the main reasons for it center on the strategy and the timings around the closure at Kwinana, and also it was announced, but the closure does come through in the second half of the year in terms of the cost savings component. Second, there is a catch-up on production volumes, and the weighting that comes, the effect of that then comes through in terms of sales in the second half. So that's the primary aspect that weights us a little bit more to the second half than was the case in 2026.

John Purtell analyst
#31

Thanks. I’d like to ask about the final item, if I may—specifically the seasonal conditions in the Australian market and what outlook you’re seeing there. Thank you.

Rico Christensen executive
#32

Yes. So only a few evenings ago I was actually at a customer event, and I received really positive feedback about how things currently stand in Australia, and there’s optimism in the market regarding the seasonal conditions. As it happened, El Niño did not produce many negative effects for the Australian market; so farmers feel positive about the current season, and they also feel positive about what that means going into the next season. Again, regarding our expectations for FY 2027, we have not seen any improvement in market conditions; we are depending on the actions we are taking to improve our numbers.

John Purtell analyst
#33

Thanks. Thanks.

Mark Watts analyst
#34

Hey, everyone. I was hoping you could give a bit more detail on the ABL refinancing — what your thinking is on timing, size, and tenor. That would be helpful. That's my first question.

Brendan Ryan executive
#35

Yeah. Thanks, Mark. Regarding the ABL, as you're aware, it currently matures in November 2027; things are moving along quite well right now as far as getting started on it. One important piece of that is having the financial year 2026 results announced, and so the work of running that process with our lenders and with ourselves gets underway from there. Our relationships with our banks are strong, we're having constructive conversations about it, and that will now begin in earnest once the results are announced this month. In terms of timeframe, we'd anticipate refinancing during the earlier half of next year, and as for terms, it will probably look much like what we had before.

Mark Watts analyst
#36

Understood. Great; regarding your CapEx figure, I believe last time in 2025, you capitalized R&D at just under AUD 100 million. How did that break down in 2026? What portion of it was maintenance R&D?

Brendan Ryan executive
#37

Yep. Thanks, Mark. Coming right up. On the CapEx, as far as intangibles go, it splits roughly fifty-fifty between PP&E and intangibles. That's about half of the overall total of AUD 160 million.

Mark Watts analyst
#38

Understood. Sorry, the sole item was on John Loop < >, again just on the crop protection side. Within the U.S., is there any sign you're still seeing of channel destocking, or has it returned to normal on that front? Any early reads you have on 2027 regarding seasonal orders and pricing? I know you said there may be some potentially better conditions or early tentative signs, but could you expand on that?

Rico Christensen executive
#39

We probably aren't seeing much activity around destocking. What we're seeing more of in the softness is likely just lower volume consumption. Of course, one of our peers announced a big, what do you call it, revaluation of inventory sitting in the channel, but that isn't volume-driven. It's more value-driven. I expect we'll be largely through destocking in North America and simply seeing a market that's consuming less volume.

Mark Watts analyst
#40

Understood. And sorry, regarding the tariff impact from last year as well, could you quantify how positive that was in the U.S., and is there, I suppose, a reversal, and how might that look?

Brendan Ryan executive
#41

Yes, Mark, on the tariffs specifically, as we all are aware, the environment has been quite dynamic over the last 18 months in this situation. That affected cost and pricing. We were fairly proactive about managing those areas, including options for sourcing and other mitigations regarding safety stock levels, and so on. On the whole, from a group standpoint, once tariffs and manufacturing disruptions are factored in, they were not material to the group overall.

Mark Watts analyst
#42

Thanks very much, guys.

Owen Birrell analyst
#43

Yeah. Morning, guys. My first question follows up on what Ramoun Lazar asked about the disruptions you saw in the fourth quarter, Laverton and Wyke. I'm just wondering whether you could give us a sense of what the actual earnings delta was from those disruptions, so that we can appreciate what the one-off benefit will be as you cycle that in the second half of 2027.

Brendan Ryan executive
#44

Yeah. As I mentioned just around the tariff from the previous inquiry, from an overall perspective, we are managing the one-offs as an aggregate. Once we take them all into account, they are one-off in nature, and the overall impact is not material to the group.

Owen Birrell analyst
#45

You're saying it isn't material, yet you've pointed out fairly consistently throughout the slide pack here that X, the impact of those, you would have seen growth in underlying EBITDA and especially in Europe. So clearly, it's material enough to swing from positive earnings growth to negative. So I'm just curious whether you can give us a sense of what that number is.

Brendan Ryan executive
#46

Well, the nature of the, I suppose we talk a bit about what kind of incidents these were. Look, as to why the unplanned downtime was extended, we had planned for some of it, but this one was extended. Its timing actually ran into the maintenance period, in terms of the annual shutdown that we're in now; that plant will be coming up quite shortly. As for Laverton, there was a chemical spill on site that we managed. Our emergency procedures kept everybody safe, and then the issue was resolved; so it meant a couple of weeks of downtime in terms of production. As I said, overall, once we take into account all these factors that are sort of untypical in nature, it isn't material to the group.

Owen Birrell analyst
#47

Okay. Turning to my second question, I'd like to focus on the leverage guidance you've given, in which you state that you will finish within the 1.5x-2x leverage target. What's really driving that leverage is lower CapEx, less working capital, and the earnings result we ought to anticipate for 2027. Regarding working capital, your net working capital is already at the low end of your 35%-40% target range, so my assumption is that no material benefit will come through there in 2027. As for lower CapEx, you've guided to under AUD 200 million. Could I ask about the earnings results that would land you at the low or high end of that target range—how confident are you that you can produce the earnings needed to stay at that 2x? Or could you end up above it? If those earnings fail to materialize, is the market so weak that you can't deliver?

Brendan Ryan executive
#48

Yes, we feel good about the earnings—sorry, the 1.5x-2x leverage range, given the outlook we've given. As you mentioned, the cash flow drivers are stronger earnings. Looking ahead to FY 2027, our capital expenditure is staying level, so the cash flow boost we got previously from lower CapEx won't repeat. On working capital, we have seen steady gains across the past two years, starting from the high point reached in the first half of 2024. In 2026, the figure came in at 36% of sales. Since our target band is 35%-40%, we have not yet reached the floor — or nearly reached it — meaning further gains remain within reach. The portfolio decisions we are making also support this, and they will bring additional working capital improvement too. It's really about ongoing enhancement, with inventory being the main area. There's still work to do and room for improvement when it comes to managing inventory; as we bring that down gradually, we'd anticipate reduced financing costs, which would add to cash flow as well. Broadly speaking, we're confident we'll land inside the 1.5 to 2 range we mentioned, though seasonal factors and FX translation risk could affect that.

Owen Birrell analyst
#49

Got it. So it sounds like you might be able to go under the 35%-40% target you set for working capital to sales. Is that what you're saying?

Brendan Ryan executive
#50

We do have opportunity there.

Owen Birrell analyst
#51

Great. All right, thanks.

Belinda Moore analyst
#52

Morning, everybody. Team, just regarding the cost savings, since it sounds like a larger share of the benefits are landing in 2028, would you expect overall crop protection growth to speed up in 2028 compared with roughly 5% growth in 2027? I see you are not assuming higher agchem prices, but do you acknowledge that they are higher as we begin this new financial year? And thirdly, on omega-3, will all the remaining oil be sold in 2027, so there is nothing further left in 2028? Do you need, say, an offtake agreement before really starting to plant again there? Thank you.

Brendan Ryan executive
#53

Thanks, Belinda. You are pushing us from 2027 to 2028. We have given the 2027 outlook. Just to remark on cost, some benefits are coming through in 2027 on the AUD 50 million. The vast majority, as we said earlier, will come through in 2028; as for what that means for crop protection profitability, look, I think we just need to consider where we are coming from; so, in 2027, we have a much healthier crop protection base in the business with higher quality revenues, switching to an improved margin mix and maintaining costs. So, we will see what 2028 holds for us, but what we are saying is we will have growth in 2027. As for omega-3, we do have remaining inventory in omega-3. The plan will be, as we communicated earlier, that would satisfy customers' requirements over 2027 and 2028. The remaining inventory is not planned to be all sold in 2027. There will be some carryover into 2028 when it comes to managing the customer requirements. So, as for the customer profile, look, discussions are healthy, the offtake is happening. We have had substantial sales in the course of 2026. The profile of continuing sales over 2027 and 2028 represents the health of the relationships.

Jonathan Snape analyst
#54

Yeah, hi, guys. Are you able to hear me fine?

Brendan Ryan executive
#55

Yep.

Jonathan Snape analyst
#56

Yeah. Right, that wasn't what I asked. Let me start by putting a couple of questions to you, and then you can respond. On the tax matter, I'd like to pin this down to a simple, one-line answer, since what you said was fairly comprehensive. Is the way to think about it that under the former management, you were perhaps taking overly aggressive tax assets for losses on the U.S. O3 platform, and some of that has already had to be unwound as an NRI, but the upshot, from what I can tell, is that almost AUD 26 million of tax assets couldn't be brought to account this year, and that will keep being an issue for the next couple of years while you shift the platform down to South America? Is that roughly what's going on?

Brendan Ryan executive
#57

No, that's not quite right. First, not overly aggressive when it comes to representing deferred tax assets in prior years. With deferred tax assets, it's more about your consumption of them, which looks forward. The risk stays around variability in your forecast. As I said, look, overall we hit our numbers, as we told you a year ago, in terms of 2026 outcomes. There's a bit of variation to that when you look at it by tax jurisdiction. But there's also some business change, which is probably the driver in the U.S., which is, as I said, the omega-3 production moving from North America, or the U.S., down to South America. Economically, overall, it doesn't change things, but where the actual profits sit does change, and so that affects the consumption of a forecast profit against the deferred tax asset on the balance sheet. Jonathan, what we're doing is staying put, not impacting what's already held on the balance sheet. It's being prudent about what we recognize given the current situation, and not adding onto the balance sheet. Compared with your over-aggressive comment earlier, what we're doing is actually the opposite. We're being quite prudent about what we bring back on. We only do that once we see the proof coming through of earnings at the group level progressively improving, and then also how that cascades down through the jurisdictions that we manage.

Jonathan Snape analyst
#58

Yeah. Okay. All right. So just regarding this crop protection business, if I take a look at it, and you've got a waterfall covering volume mix, price, that sort of thing, at both the revenue and EBITDA level. If I looked at that for the first half, I think volume and mix was roughly a 7% headwind. Then looking at the full year, it's around 13.5%. So that was over 20% as a year-on-year headwind in the second half, roughly. If I look at most of your peers, they report volumes down around that 7% level in aggregate across that same period. Did you see, I guess what I'm trying to work out is whether 7% was market and 13%, 14% is what you're doing on SKU rationalization? Because from what I can gather here, it looked like a fair weakening in the fourth quarter, especially in fungicides in the EU, and U.S. demand too; but is that the right way to think about it, or was there more market, less internal stuff?

Rico Christensen executive
#59

Well, I'd say, Jonathan, it's probably slightly more on what we choose to do and then what's happening in the market. But I'd say that maybe our profile versus peers is a bit different in product mix. So we're probably not quite seeing the same volume decline across the rest of the business. Because remember, what we're trying to do is lower margin; we're trying to cut lower-margin sales, but grow higher-margin sales. So that sort of, call it, muddles the mix and the calculations a little bit. So I'd say we're probably declining more on lower-margin stuff than what you're seeing in the numbers, and then we're making up for that by growing sales of higher-margin products, if that makes sense.

Jonathan Snape analyst
#60

Yeah. Looking ahead to this year, it sounds like the fourth quarter was pretty weak across the board, especially in the EU, where there was that dry spell. If you assume things return to normal, should some of that come back, from a market standpoint? Do you sort of build that in? You describe it as a normal kind of assumption. Would you assume a normal fourth quarter when putting together your guidance? There's a typical fungicide selling window in the EU, and the U.S. doesn't seem to have the same problems it had this year?

Rico Christensen executive
#61

Well, as you know, Jonathan, our business is largely, really depends on or is affected by the weather. We can't predict what the weather will be 12 months out. What we do in planning for the year ahead is build our plans on what we see right now, whatever that happens to be; that's how we put our forecast together; we aren't assuming conditions get better or get worse. The improvements and the growth in the EBITDA we expect for FY 2027 really come from, call it, self-help, the things we're doing to make our business better by taking cost out. That's what's driving the growth.

Jonathan Snape analyst
#62

Got it. Got it. All right. Appreciate it.

Rico Christensen executive
#63

Thanks, Abby. Like I mentioned at the start, this is a solid outcome. Profits came in higher, their quality is stronger, cash flow is up substantially, and leverage now sits at two times. That tells us our strategy refresh is paying off. It has hit every key metric, and we've recorded better EBITDA in every business segment and region throughout crop protection and seeds. We’re also aware there’s additional work ahead; those enhancements will carry into FY 2027, when we anticipate better returns as well as gains in cash flow and EBITDA. With that, thank you for joining the call, and thanks as well to Abby for hosting us today.

Operator operator
#64

Ladies and gentlemen, that brings today's call to a close, and we appreciate your joining us. You can disconnect at this time.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Nufarm Limited transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Nufarm Limited earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.